EHC Quote, Financials, Valuation and Earnings

Kindly MD has a net margin of 8.01% compared to Encompass Health's net margin of -156.54%. Encompass Health's return on equity of 17.39% beat Kindly MD's return on equity of -201.03%.

Encompass Health has a consensus price target of --, signalling upside risk potential of 23.71%. On the other hand Kindly MD has an analysts' consensus of -- which suggests that it could fall by --. Given that Encompass Health has higher upside potential than Kindly MD, analysts believe Encompass Health is more attractive than Kindly MD.

Encompass Health has a beta of 0.876, which suggesting that the stock is 12.393% less volatile than S&P 500. In comparison Kindly MD has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.66%. Kindly MD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 17.16% of its earnings as a dividend. Kindly MD pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.4B, which are larger than Kindly MD quarterly revenues of $647.9K. Encompass Health's net income of $108.2M is higher than Kindly MD's net income of -$1M. Notably, Encompass Health's price-to-earnings ratio is 22.75x while Kindly MD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.84x versus 2.10x for Kindly MD. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of 8.01% compared to Encompass Health's net margin of 3.8%. Encompass Health's return on equity of 17.39% beat Pediatrix Medical Group's return on equity of -30.86%.

Encompass Health has a consensus price target of --, signalling upside risk potential of 23.71%. On the other hand Pediatrix Medical Group has an analysts' consensus of -- which suggests that it could grow by 18.27%. Given that Encompass Health has higher upside potential than Pediatrix Medical Group, analysts believe Encompass Health is more attractive than Pediatrix Medical Group.

Encompass Health has a beta of 0.876, which suggesting that the stock is 12.393% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.570, suggesting its more volatile than the S&P 500 by 56.979%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.66%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 17.16% of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.4B, which are larger than Pediatrix Medical Group quarterly revenues of $511.2M. Encompass Health's net income of $108.2M is higher than Pediatrix Medical Group's net income of $19.4M. Notably, Encompass Health's price-to-earnings ratio is 22.75x while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.84x versus 0.57x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

Tenet Healthcare has a net margin of 8.01% compared to Encompass Health's net margin of 9.22%. Encompass Health's return on equity of 17.39% beat Tenet Healthcare's return on equity of 45.56%.

Encompass Health has a consensus price target of --, signalling upside risk potential of 23.71%. On the other hand Tenet Healthcare has an analysts' consensus of $179.46 which suggests that it could grow by 38.36%. Given that Tenet Healthcare has higher upside potential than Encompass Health, analysts believe Tenet Healthcare is more attractive than Encompass Health.

Encompass Health has a beta of 0.876, which suggesting that the stock is 12.393% less volatile than S&P 500. In comparison Tenet Healthcare has a beta of 2.060, suggesting its more volatile than the S&P 500 by 105.97%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.66%. Tenet Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 17.16% of its earnings as a dividend. Tenet Healthcare pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.4B, which are smaller than Tenet Healthcare quarterly revenues of $5.1B. Encompass Health's net income of $108.2M is lower than Tenet Healthcare's net income of $472M. Notably, Encompass Health's price-to-earnings ratio is 22.75x while Tenet Healthcare's PE ratio is 4.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.84x versus 0.62x for Tenet Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of 8.01% compared to Encompass Health's net margin of -16.13%. Encompass Health's return on equity of 17.39% beat The Oncology Institute's return on equity of -163.45%.

Encompass Health has a consensus price target of --, signalling upside risk potential of 23.71%. On the other hand The Oncology Institute has an analysts' consensus of -- which suggests that it could grow by 795.26%. Given that The Oncology Institute has higher upside potential than Encompass Health, analysts believe The Oncology Institute is more attractive than Encompass Health.

Encompass Health has a beta of 0.876, which suggesting that the stock is 12.393% less volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.66%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 17.16% of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.4B, which are larger than The Oncology Institute quarterly revenues of $99.9M. Encompass Health's net income of $108.2M is higher than The Oncology Institute's net income of -$16.1M. Notably, Encompass Health's price-to-earnings ratio is 22.75x while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 1.84x versus 0.04x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.